HGEN News and Press, Humanigen Inc. From 06/03/21

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced it will present at the 2021 LD Micro Invitational XI, he...

Humanigen (HGEN) announces that the company has submitted an application to the U.S. FDA requesting Emergency Use Authorization ((EUA)) for lenzilumab for the treatment of patients hospitalized with COVID-19.The EUA application follows positive results from the LIVE-AIR Phase 3 clinical trial...

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab, today announced that the company submitted an...

Humanigen, Inc. (Nasdaq: HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that granulocyte macrophage-colony stimulating f...

Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...

Humanigen (HGEN) and Chime Biologics have entered into a manufacturing services agreement to produce Humanigen's COVID-19 therapy lenzilumab's bulk drug substance and drug product.The agreement follows receipt of requisite regulatory authorizations in regions outside of the United States...

Humanigen, Inc. (Nasdaq:HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, and Chime Biologics (“Chime&#x...

Humanigen (HGEN): Q1 GAAP EPS of -$1.25 misses by $0.61.Revenue of $0.49MCash and cash equivalents of $92.9M.Press Release For further details see: Humanigen EPS misses by $0.61

Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today reported financial results for...

Oppenheimer has initiated shares of Humanigen (HGEN) with an outperform rating as its experimental COVID-19 therapy is "the most investible approach to the maturing COVID-19 pandemic."The firm's $30 price target implies upside of around ~39% based on today's close.Analyst Kevin DeGeeter says ...